1033748-75-2

Upstream product

• 934536-10-4 (trans)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 
• 501-53-1 benzyl chloroformate 
• 907544-20-1 (3S,4R)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 

Downstream Products

• 1034057-93-6 benzyl ((3S,4R)-3-fluoropiperidin-4-yl)carbamate hydrochloride 
• 1033748-74-1 benzyl (3S,4R)-1-[(2-tert-butyldimethylsilyloxy)ethyl]-3-fluoropiperidin-4-ylcarbamate 
• 1351866-17-5 C₁₉H₂₇FN₂O₄ 
• 1351866-20-0 C₁₅H₂₁FN₂O₃S 
• 1351866-30-2 C₂₀H₂₉FN₂O₅S 
• 1351866-19-7 C₁₅H₁₉FN₆O 
• 1351866-29-9 C₂₀H₂₇FN₆O₃ 

Relevant academic research and scientific papers

BENZAMIDE CGRP RECEPTOR ANTAGONISTS

The present invention is directed to benzamide compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced p K a: Antibacterial agents with an improved safety profile

Novel non-fluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) are of interest for the development of new antibacterial agents that are not impacted by target-mediated cross-resistance with fluoroquinolones. N-L

2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS

The present invention relates to compounds of Formula (I) : and pharmaceutically acceptable salts thereof, to their use in the treatment of bacterial infections, and to their methods of preparation.